Therefore, despite well‐established safety and tolerance of PDE5 inhibitors, the unclear role of these medications in clinical cardiac pathologies has contributed to the lack of indications for prescribing PDE5 inhibitors in the treatment of cardiovascular disease [18] and has led to an insert package warning about potential risks in patients with coronary disease. This evidence concerns the gene PDE5A and cardiovascular disorder.